Skip to Content

AstraZeneca PLC

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
GBX 53,724.00NvnnFshxvsjr

Drug Pricing Policy in the Inflation Reduction Act a Moderate But Manageable Negative to Biopharma

The likelihood of drug-pricing policy changes in the United States changed dramatically over the course of July, and we are now assessing the impact of the various measures included in the Inflation Reduction Act of 2022 in our Big Biopharma valuation models. Assuming the bill is eligible to pass via reconciliation (the Senate parliamentarian is reviewing the bill), we think Democrats will be able to pass the Senate bill, paving the way for it to be signed into law. Overall, we don’t expect major changes to our fair value estimates or moat ratings, as the changes net out to a moderate negative that we believe is manageable, likely through a combination of cost-cutting, agreements with generic firms for limited authorized generic launches (to avoid the list for negotiated drugs), and higher launch prices (to counter pressure on price increases and earlier declines due to negotiation).

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of AZN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center